Marking more than 15 years of partnership with Europe’s drug discovery community, Viva Biotech is reinforcing its dedication to the region through operational consistency, steady growth, and scalable collaboration. As the European biopharmaceutical sector undergoes major structural transformation, the importance of a dependable, long-term research partner has become increasingly critical to sustaining progress in key innovation initiatives.

Ensuring Stability in a Shifting Environment
Across Europe, clients see Viva Biotech as more than a service provider—they regard it as a trusted partner and an extension of their own teams. With a strong UK presence and specialized regional teams, the company delivers responsive, well-coordinated support throughout the complexities of the drug discovery process.

Driving Innovation Through Expanded Integrated Capabilities
To support partners in moving from early discovery to candidate selection with greater confidence, Viva Biotech continues to expand its platforms—positioning itself as a fully integrated partner across discovery, development, and manufacturing.

Shaping the Future of European Drug Discovery
The past 15 years in Europe have been marked by scientific excellence and strong, trust-based collaborations. Viva Biotech looks forward to continuing this journey, partnering with the next generation of innovators to drive future breakthroughs in drug discovery.

Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has announced the renewal and extension of its long-term strategic partnership with Bristol Myers Squibb through 2035. The enhanced agreement significantly expands the range of integrated services offered across the entire drug development value chain. These capabilities span early discovery—including chemistry, biology, and drug metabolism and pharmacokinetics—through translational research, pharmaceutical development, manufacturing, clinical trial support, and data and IT services.

This comprehensive integration is designed to support a smooth transition from early research to commercial production. The renewed collaboration represents the next stage in the relationship, further strengthening Syngene’s role as a trusted partner providing end-to-end scientific and manufacturing solutions.

Commenting on the extension, Peter Bains, Managing Director and Chief Executive Officer of Syngene International Ltd., said that the partnership with Bristol Myers Squibb, which has now exceeded 25 years, is built on strong scientific capabilities, dependable execution, and a shared vision to deliver breakthrough therapies. He noted that extending the agreement through 2035 allows both organizations to take a long-term, forward-looking approach to developing new infrastructure and capabilities over the next decade.

This long-range planning, he added, is central to the strategic value of the partnership. Syngene looks forward to continuing its support of Bristol Myers Squibb’s upcoming discovery, development, and manufacturing initiatives aimed at improving patient outcomes globally.

Payal Sheth, Senior Vice President, Therapeutic Discovery Sciences at Bristol Myers Squibb, emphasized that patient needs remain at the core of the company’s mission. She highlighted the importance of the long-standing collaboration with Syngene in helping advance Bristol Myers Squibb’s scientific goals. According to her, the expanded scope of the partnership underscores the company’s commitment to driving innovative science through closer integration of research, development, and manufacturing capabilities, ultimately accelerating the delivery of transformative therapies to patients worldwide.

The partnership between Syngene and Bristol Myers Squibb dates back to 1998 and led to the creation of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), Syngene’s first dedicated R&D facility, which became fully operational in 2009. Over time, BBRC has grown into a key strategic research hub for Bristol Myers Squibb, offering integrated expertise across areas such as target identification, lead discovery and optimization, pharmaceutical development, molecular and cellular biology, protein sciences, assay development, and clinical biomarkers. Today, the center employs approximately 700 Syngene scientists who operate as an extension of Bristol Myers Squibb’s global research teams, contributing to discovery, preclinical development, and patent filings across therapeutic areas including cardiovascular disease, fibrosis, immunology, and oncology.

Since its establishment, BBRC has been instrumental in speeding the advancement of new compounds from early research through first-in-human studies, helping Bristol Myers Squibb shorten development timelines and manage overall costs more effectively.

About Syngene
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is a fully integrated research, development, and manufacturing services provider supporting clients across the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals industries. With a workforce of more than 8,200 employees, including around 5,600 scientists, Syngene combines deep scientific expertise with strong data security practices and world-class manufacturing capabilities to accelerate innovation, reduce time-to-market, and lower development costs.

Operating more than 2.5 million square feet of specialized discovery, development, and manufacturing infrastructure across India and the United States, Syngene partners with approximately 400 global customers. These include innovative biotech firms as well as leading multinational organizations such as Bristol Myers Squibb, GSK, Zoetis, and Merck KGaA.

Click here to know more about the company’s latest Environmental, Social, and Governance (ESG) report.

Media Contacts:
Vijay Jeevanandham
Syngene International Limited
M: +91 8310914552
E: Vijay.Jeevanandham@syngeneintl.com

Alex Heeley / Abdul Khalifeh
De Facto Communications
T: +44 (0) 203 735 8165 / +44 (0) 7834784764
E: a.khalifeh@defacto.co.uk
E: a.heeley@defacto.co.uk

Ribo Life Science Co., Ltd, a pioneer in the development of small interfering RNA (siRNA) therapies, has successfully debuted on the Main Board of the Hong Kong Stock Exchange. This achievement represents an important step forward for the capitalization of China’s biopharmaceutical sector in the siRNA space and brings renewed momentum to the industry.

Through its global initial public offering, Ribo issued 31,610,400 shares at a price of HKD 57.97 per share, generating gross proceeds exceeding HKD 1.8 billion. Investor demand was exceptionally strong, with the Hong Kong public offering oversubscribed by more than 100 times and the international placement receiving 16.7 times subscription. These results highlight robust global investor confidence in both the siRNA therapeutic landscape and Ribo’s technological strength.

The funds raised will provide substantial financial backing for the Company’s core operations and future growth. The offering also secured participation from 12 cornerstone investors, including Arc Avenue, Ivy Rock, Springs Capital, China Asset Management, Dacheng International, Dacheng Fund, and Taikang Life Insurance, underscoring institutional confidence in Ribo’s long-term development strategy.

Dr. Zicai Liang, Founder, Chairman, and Chief Executive Officer of Ribo, stated that the Company’s listing in Hong Kong marks a defining moment in its evolution. He expressed appreciation to global investors for their continued support and emphasized that Ribo will utilize international capital markets to speed up global clinical development and commercialization of its siRNA therapies, enhance its technological platforms, deliver innovative treatments to patients worldwide, and generate long-term value for shareholders.

The net proceeds from the IPO will be primarily allocated to four strategic areas: advancing global multicenter clinical trials for key products; funding preclinical and clinical pipeline development; upgrading siRNA delivery systems and related technology platforms; and strengthening working capital and general corporate operations.

Ribo has established a fully integrated research and development platform supported by proprietary intellectual property. Its proprietary liver-targeting RiboGalSTAR delivery technology has enabled multiple drug candidates to progress into Phase II clinical studies. The Company operates R&D centers in Suzhou, Beijing, and Gothenburg, Sweden, forming a global research network that supports the full drug development process, from discovery through international clinical trials.

The successful listing was jointly sponsored by China International Capital Corporation and Citigroup, whose expertise and support contributed to Ribo’s smooth entry into the public capital markets.